Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Abstract: A plasma processing apparatus 10 includes: a first support member 81 for raising and lowering an object to be processed 200, a second support member 82 supporting a cover 70, a drive part 120 for raising and lowering the cover 70 via the second support member 82. The drive part 120, when raising the cover 70 from a lowered position to a raised position, in a first process, raises the second support member 82 without raising the first support member 81, and thus to raise the cover 70 without raising the object to be processed 200, and in a second process, raises the first and second support members 81 and 82 integrally, and thus to raise the cover 70 from the beginning of the second process, and raise the object to be processed 200 from the beginning of or after the beginning of the second process.

Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies.

Abstract: An operational amplifier circuit including a main circuit, a compensation capacitor, a power circuit, and a set of switches is disclosed. The main circuit has an output terminal. The compensation capacitor has a first end connected to an internal node of the main circuit and a second end connected to the output terminal of the main circuit. The power circuit provides a current or a voltage as predetermined. The set of switches connects the power circuit to the compensation capacitor. When the main circuit is not in an output state, the set of switches is switched to allow the power circuit to provide the current or voltage to the compensation capacitor. When the main circuit is in the output state, the set of switches is switched to disconnect the power circuit from the compensation capacitor and allow the main circuit to return to an output circuit state and operate normally.

Abstract: A source driver and an operation method thereof are provided. The operation method includes following steps. A data signal is provided to the source driver. The operating current of the source driver is reduced to an abnormal operating level in period from the source driver is reset to before a pixel data of the source driver is appeared in the data signal. The operation current of the source driver is restored to a normal operating level when the pixel data of the source driver is appeared in the data signal.

Abstract: An operational amplifier circuit including a main circuit, a compensation capacitor, a power circuit, and a set of switches is disclosed. The main circuit has an output terminal. The compensation capacitor has a first end connected to an internal node of the main circuit and a second end connected to the output terminal of the main circuit. The power circuit provides a current or a voltage as predetermined. The set of switches connects the power circuit to the compensation capacitor. When the main circuit is not in an output state, the set of switches is switched to allow the power circuit to provide the current or voltage to the compensation capacitor. When the main circuit is in the output state, the set of switches is switched to disconnect the power circuit from the compensation capacitor and allow the main circuit to return to an output circuit state and operate normally.

Abstract: A method is provided for expressing recombinant proteins and polypeptides such as human serum albumin (HSA), human growth hormone (HGH), or insulin-like growth factor-I (IGF-1) in large quantities using a methylotropic or ethylotropic microorganism such as a yeast, bacteria or fungi using a dilute methanol or ethanol feeding strategy which provides for a lower flash point and can minimize the likelihood of dangerous explosion. The present invention is thus advantageous because it allows recombinant proteins to be produced on a large scale in non-explosion proof plants without the hazards associated with the use of 100% methanol which generally Ces not meet OSHA requirements, and can thus allow the safe and efficient production of large quantities of recombinant proteins and other biomaterials at a far reduced cost.